Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.43 |
| ▸ | KDM1A | O60341 | 5/20 | 0.43 |
| ▸ | XDH | P47989 | 5/20 | 0.39 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129334 | 0.86 | MEP1B (0.49) | HDAC1KDM1AXDHMEP1BSCN10A | |
| SCHEMBL5131869 | 0.84 | MEP1B (0.43) | MEP1BADAM17 | |
| SCHEMBL405190 | 0.84 | XDH (0.50) | HDAC1KDM1AXDH | |
| SCHEMBL10286652 | 0.79 | SDCBP (0.49) | HDAC1MEP1B | |
| SCHEMBL2258599 | 0.74 | MEP1B (0.54) | HDAC1MEP1B | |
| SCHEMBL399832 | 0.73 | ALDH1A1 (0.52) | HDAC1MEP1BADAM17 | |
| SCHEMBL404304 | 0.73 | ALDH1A1 (0.52) | HDAC1MEP1BADAM17 | |
| SCHEMBL399676 | 0.73 | ALDH1A1 (0.52) | HDAC1MEP1BADAM17 | |
| SCHEMBL12064314 | 0.73 | ALDH1A1 (0.52) | HDAC1MEP1BADAM17 | |
| SCHEMBL402593 | 0.72 | BACE1 (0.47) | MEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | HDAC1 824/4885KDM1A 4512/4885XDH 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.